Friday, July 10, 2026

pharma · Colorectal Cancer · Lymphoma, Extranodal NK-T-Cell

Samsung Bioepis

Samsung Bioepis clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Yeonsu-gu, Incheon 21987, KR HQ
2012 Founded
1,589 Employees
EMA registrant Type
Company details
Status
Public
HQ
Yeonsu-gu, Incheon 21987, KR
Founded
2012
Employees
1,589
Programs
24
Drugs
34
Patents
0
Intelligence · Clinical Programs

Samsung Bioepis projects

3 ClinicalTrials.gov programs sponsored by Samsung Bioepis.

Samsung Bioepis has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. E303-1001

    Samsung Bioepis NL B.V.

    advanced refractory solid tumors

    phase 1 other active

    1 trial
  2. PNEUMOSTEM®

    Samsung Bioepis NL B.V.

    Pulmonary Arterial Hypertension (PAH)

    phase 1 mab active

    1 trial
  3. SB27-1005

    Samsung Bioepis NL B.V.

    Non-small cell lung cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Samsung Bioepis have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.